Connect with us
European Gaming Congress 2024

Fintech PR

James Shanahan, Ph.D., to lead Bryant University Data Science Initiative

Published

on

Reading Time: 3 minutes

 

Bryant University announces the appointment of James (Jimi) Shanahan, Ph.D., as the inaugural John ’01H and Jeanne Rowe Professor of Data Science, effective summer 2019. Shanahan brings 30 years of leading-edge entrepreneurship, data science expertise, and academic accomplishment to the new role. Bryant’s curriculum, with its unique integration of business and liberal arts, is perfectly suited for this interdisciplinary course of study. The University launched an innovative undergraduate program in Data Science in fall 2017 to meet growing demand in one of the fastest growing sectors worldwide.

“If one looks to the future impact of rapid advances in Artificial Intelligence (AI), robotics, block chain, the ‘internet of things,’ and other emerging technologies, it is clear that higher education must take the lead in preparing graduates for the many challenges and opportunities these developments will create,” says Bryant University President Ronald K. Machtley.

“I am honored to be joining the Bryant University faculty,” says Shanahan. “The workforce of the future will require constant up-skilling, and employee digital dexterity will outweigh tenure and experience. Bryant recognizes this and is well-positioned to prepare its students with the technical and critical thinking skills needed to successfully compete in the digital marketplace.”

“Jeanne and I have been delighted to help Bryant University because it does so much to help young people acquire the skills that make them productive in today’s ever changing society,” says John Rowe ’01H. “We are especially pleased that Bryant’s first Rowe Professor, Dr. James Shanahan, is expert in the rapidly moving fields of big data and artificial intelligence. Sorting the real from the fantastic in these areas will be a vital part of tomorrow’s education.”

Advertisement
Stake.com

Throughout his career, Shanahan has split his time between industry and academia, gaining vast experience developing cutting-edge information management systems that harness deep learning, statistical machine learning, and information retrieval in domains such as web search, ecommerce, retail, computational advertising, and security. As a teacher and scholar, he most recently served as a founding faculty member of the Masters in Data Science programs at University of California, Berkeley, and Indiana University. He has also held visiting positions at University of California, Santa CruzRutgers University, and Syracuse University.

Provost and Chief Academic Officer Glenn Sulmasy, J.D., LL.M., notes that with Shanahan’s leadership the new Data Science program will capitalize on the Bryant reputation of bringing together the best of data science and business, reflecting the emerging demands of the 21st century workforce. “The Bryant Data Science initiative is interdisciplinary in nature, including a rich experiential component, and aligns perfectly with Bryant’s strengths and innovative culture. The addition of Jimi Shanahan to our outstanding faculty will help advance the program and prepare our students, both intellectually and practically, for the surge in marketplace demand for skilled data scientists and analysts.”

Madan Annavarjula, Ph.D., Dean of the College of Business, sees Shanahan’s appointment as an important investment and opportunity for Bryant. “Our undergraduate Data Science program is rapidly evolving as one of the most distinguished in the country for students who want to pursue a career in this area.”

An accomplished entrepreneur and business leader, Shanahan has co-founded companies that leverage AI, machine learning, deep learning, and computer vision in areas such as digital advertising, web search, and smart cameras. These firms include Church and Duncan Group, Inc., a boutique consultancy in large scale data science founded in 2007 in San Francisco, CA; RTBFast, a real-time bidding engine infrastructure play for digital advertising systems founded in 2012 in San Francisco, CA; and Document Souls, an anticipatory information system founded in 1999 in Grenoble, France. He has also served as SVP of Data Science and Chief Scientist at NativeX in San Francisco, CA, a mobile ad network that was acquired by MobVista. In addition, he has held positions at Adobe Research, Turn Inc., Xerox Research, Mitsubishi Research, and Clairvoyance Corp. He’s been part of 20 U.S. patent filings at Xerox, AT&T, Just Systems, and InferSystems.

A prolific scholar, Shanahan has published eight books, including “Soft computing for knowledge discovery: introducing Cartesian granule features” in 2000, which is considered one of the seminal texts for advanced undergraduates, professionals and researchers in computer science.His newest book is “Machine Learning at Scale.” He has published more than 45 peer-reviewed articles in prestigious publications such as the Journal of Intelligent and Robotic Systems; seven book chapters including “Digital Advertising: an information science perspective” in the textbook “Advanced Topics in Information Retrieval;” and scores of conference papers including “Parsing Spoken Local Queries using Committees” at the Fourth ACM (Association of Computing Machinery) International Conference on Web Search and Data Mining. Shanahan is a sought-after expert speaker at conferences, businesses, and universities around the world.

Advertisement
Stake.com

Shanahan completed his Bachelor of Science in Computer Science at University of Limerick in Ireland, and earned his Ph.D. in Engineering and Mathematics at University of Bristol in the U.K. He is an EU Marie Curie Fellow, and in 2011, he was selected as a member of the Silicon Valley 50 (Top 50 Irish Americans in Technology).

 

SOURCE Bryant University

Fintech PR

Invitation to presentation of EQT AB’s Q1 Announcement 2024

Published

on

invitation-to-presentation-of-eqt-ab’s-q1-announcement-2024

STOCKHOLM, April 5, 2024 /PRNewswire/ — EQT AB’s Q1 Announcement 2024 will be published on Thursday 18 April 2024 at approximately 07:30 CEST. EQT will host a conference call at 08:30 CEST to present the report, followed by a Q&A session.

The presentation and a video link for the webcast will be available here from the time of the publication of the Q1 Announcement.

To participate by phone and ask questions during the Q&A, please register here in advance. Upon registration, you will receive your personal dial-in details.

The webcast can be followed live here and a recording will be available afterwards.

Information on EQT AB’s financial reporting

Advertisement
Stake.com

The EQT AB Group has a long-term business model founded on a promise to its fund investors to invest capital, drive value creation and create consistent attractive returns over a 5 to 10-year horizon. The Group’s financial model is primarily affected by the size of its fee-generating assets under management, the performance of the EQT funds and its ability to recruit and retain top talent.

The Group operates in a market driven by long-term trends and thus believes quarterly financial statements are less relevant for investors. However, in order to provide the market with relevant and suitable information about the Group’s development, EQT publishes quarterly announcements with key operating numbers that are relevant for the business performance (taking Nasdaq’s guidance note for preparing interim management statements into consideration). In addition, a half-year report and a year-end report including financial statements and further information relevant for investors is published. Finally, EQT also publishes an annual report including sustainability reporting.

Contact
Olof Svensson, Head of Shareholder Relations, +46 72 989 09 15
EQT Shareholder Relations, [email protected]

Rickard Buch, Head of Corporate Communications, +46 72 989 09 11
EQT Press Office, [email protected], +46 8 506 55 334

This information was brought to you by Cision http://news.cision.com

Advertisement
Stake.com

https://news.cision.com/eqt/r/invitation-to-presentation-of-eqt-ab-s-q1-announcement-2024,c3956826

The following files are available for download:

https://mb.cision.com/Main/87/3956826/2712771.pdf

Invitation to presentation of EQT AB’s Q1 Announcement 2024

https://news.cision.com/eqt/i/eqt-ab-group,c3285895

Advertisement
Stake.com

EQT AB Group

 

View original content:https://www.prnewswire.co.uk/news-releases/invitation-to-presentation-of-eqt-abs-q1-announcement-2024-302109147.html

Continue Reading

Fintech PR

Kia presents roadmap to lead global electrification era through EVs, HEVs and PBVs

Published

on

kia-presents-roadmap-to-lead-global-electrification-era-through-evs,-hevs-and-pbvs
  • Kia drives forward transformation into ‘Sustainable Mobility Solutions Provider’
  • Roadmap enables Kia to proactively respond to uncertainties in mobility industry landscape, including changes in EV market
  • Company to expand EV line-up with more models; enhance HEV line-up to manage fluctuation in EV demand
    • Goal to sell 1.6 million EVs annually in 2030, introducing 15 models
    • PBV to play a key role in Kia’s growth, targeting 250,000 PBV sales annually by 2030 with PV5 and PV7 models
  • Kia to invest KRW 38 trillion by 2028, including KRW 15 trillion for future business
  • 2024 business guidance : KRW 101 tln in revenue with KRW 12 tln in operating profit; operating profit margin of 11.9% on sales of 3.2 million units globally
  • CEO reaffirms Kia’s commitment to ESG management

SEOUL, South Korea, April 5, 2024 /PRNewswire/ — Kia Corporation (Kia) today shared an update on its future strategies and financial targets at its CEO Investor Day in Seoul, Korea.

Based on its innovative achievements in the years since the announcement of mid-to-long-term business initiatives, Kia is focusing on updating its 2030 strategy announced last year and further strengthening its business strategy in response to uncertainties across the global mobility industry landscape.

During the event, Kia updated its mid-to-long-term business strategy with a focus on electrification, and its PBV business. Kia reiterated its 2030 annual sales target of 4.3 million units, including 1.6 million units of electric vehicles (EVs). The 2030 4.3 million annual sales target is 34.4 percent higher than the brand’s 2024 annual goal of 3.2 million units.

The company also plans to become a leading EV brand by selling a higher percentage of electrified models among its total sales, including hybrid electric vehicles (HEV), plug-in hybrid (PHEV), and battery EVs, projecting electrified model sales of 2.48 million units annually or 58 percent of Kia’s total sales in 2030.

“Following our successful brand relaunch in 2021, Kia is enhancing its global business strategy to further the establishment of an innovative EV line-up and accelerate the company’s transition to a sustainable mobility solutions provider,” said Ho Sung Song, President and CEO of Kia. “By responding effectively to changes in the mobility market and efficiently implementing mid-to-long-term strategies, Kia is strengthening its brand commitment to the wellbeing of customers, communities, the global society, and the environment.”

Advertisement
Stake.com

Photo – https://mma.prnewswire.com/media/2380039/Photo_1__2024_CEO_Investor_Day.jpg
PDF – https://mma.prnewswire.com/media/2380040/Press_Release__2024_Kia_CEO_Investor_Day_240405.pdf

Cision View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/kia-presents-roadmap-to-lead-global-electrification-era-through-evs-hevs-and-pbvs-302109142.html

Continue Reading

Fintech PR

BioVaxys Technology Corp. Provides Bi-Weekly MCTO Status Update

Published

on

biovaxys-technology-corp.-provides-bi-weekly-mcto-status-update

VANCOUVER, BC, April 4, 2024 /PRNewswire/ — BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) (the “Company“) is providing this bi-weekly update on the status of the management cease trade order granted on February 29, 2024 (the “MCTO“), by its principal regulator, the Ontario Securities Commission (the “OSC“), under National Policy 12-203 – Management Cease Trade Orders (“NP 12-203“), following the Company’s announcement on February 21, 2024 (the “Default Announcement“), that it was unable to file its audited annual financial statements for the year ended October 31, 2023, its management’s discussion and analysis of financial statements for the year ended October 31, 2023, its annual information form for the year ended October 31, 2023, and related filings (collectively, the “Required Annual Filings“). Under National Instrument 51-102, the Required Annual Filings were required to be made no later than February 28, 2024.

As a result of the delay in filing the Required Annual Filings, the Company was unable to file its interim financial statements for the three months ended January 31, 2024, its management’s discussion and analysis of financial statements for the three months ended January 31, 2024, and related filings (collectively, the “Required Interim Filings“). Under National Instrument 51-102, the Required Interim Filings were required to be made no later than April 1, 2024.

The Company anticipates filing the Required Annual Filings by April 30, 2024. The auditor of the Company requires additional time to complete its audit of the Company, including the Company’s recent acquisition of all intellectual property, immunotherapeutics platform technologies, and clinical stage assets of the former IMV Inc. that closed on February 16, 2024. In addition, the Company anticipates filing the Required Interim Filings immediately after the filing of the Required Annual Filings.

Except as herein disclosed, there are no material changes to the information contained in the Default Announcement. In addition, (i) the Company is satisfying and confirms that it intends to continue to satisfy the provisions of the alternative information guidelines under NP 12-203 and issue bi-weekly default status reports for so long as the delay in filing the Required Annual Filings and/or Required Interim Filings is continuing, each of which will be issued in the form of a press release; (ii) the Company does not have any information at this time regarding any anticipated specified default subsequent to the default in filing the Required Annual Filings and Required Interim Filings; (iii) the Company is not subject to any insolvency proceedings; and (iv) there is no material information concerning the affairs of the Company that has not been generally disclosed.

About BioVaxys Technology Corp.

Advertisement
Stake.com

BioVaxys Technology Corp. (www.biovaxys.com), a biopharmaceuticals company registered in British Columbia, Canada, is a clinical-stage biopharmaceutical company dedicated to improving patient lives with novel immunotherapies based on the DPX™ immune-educating technology platform and it’s HapTenix© ‘neoantigen’ tumor cell construct platform, for treating cancers, infectious disease, antigen desensitization, and other immunological fields. The Company’s clinical stage pipeline includes maveropepimut-S which is in Phase II clinical development for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum resistant ovarian cancer, and BVX-0918, a personalized immunotherapeutic vaccine using it proprietary HapTenix© ‘neoantigen’ tumor cell construct platform which is soon to enter Phase I in Spain for treating refractive late-stage ovarian cancer. The Company is also capitalizing on its tumor immunology know-how and creation of a unique library of T-lymphocytes & other datasets post-vaccination with its personalized immunotherapeutic vaccines to utilize predictive algorithms and other technologies to identify new targetable tumor antigens. BioVaxys common shares are listed on the CSE under the stock symbol “BIOV” and trade on the Frankfurt Bourse (FRA: 5LB) and in the US (OTCQB: BVAXF). For more information, visit www.biovaxys.com and connect with us on X and LinkedIn.

ON BEHALF OF THE BOARD

Signed “James Passin
James Passin, Chief Executive Officer
Phone: +1 646 452 7054

Logo – https://mma.prnewswire.com/media/1430981/BIOVAXYS_Logo.jpg

Cision View original content:https://www.prnewswire.co.uk/news-releases/biovaxys-technology-corp-provides-bi-weekly-mcto-status-update-302108920.html

Advertisement
Stake.com
Continue Reading

Trending